Clinical trial

Effect of NNC 90-1170 on Hypoglycaemic Counterregulation During Stepwise Hypoglycaemic Clamp in Type 2 Diabetic Subjects. A Double-blind, Placebo-controlled, Randomised, 2-period Cross-over Trial

Name

NN2211-1224

Description

This trial is conducted in Europe. The aim of this trial is to examine the effect of NNC 90-1170 on the hypoglycaemic counterregulation in subjects with type 2 diabetes.

Trial arms

Trial start

2001-04-01

Estimated PCD

2001-11-01

Trial end

2001-11-01

Status

Completed

Phase

Early phase I

Treatment

liraglutide

Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement

Arms:

NNC 90-1170

Other names:

NNC 90-1170

placebo

Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement

Arms:

Placebo

Size

Primary endpoint

Area under the Curve (AUC) glucagon

Eligibility criteria

age: minimum 30, maximum 75 years

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 19, 'type': 'ACTUAL'}}

Updated at

2024-02-01

1 organization

2 products

3 indications

Organization

Product

Indication

Indication

Indication

Product